BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...in IFM Therapeutics Inc., the post-acquisition spinout IFM Therapeutics LLC...
...for inflammation was spun out into the IFM Therapeutics LLC...
...TMEM173) - Transmembrane protein 173 Paul Bonanos IFM Therapeutics Inc. IFM Therapeutics LLC Scorpion...
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...subsequent products (see “BMS Expanding I-O Portfolio” ). After spinning out of IFM Therapeutics Inc., IFM Therapeutics LLC...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

...space has a history of attracting pharma BD. In addition to the Jecure acquisition, inflammasome-focused IFM Therapeutics LLC...
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...Ilaris canakinumab for various autoimmune and inflammatory indications. Last year, Novartis acquired two subsidiaries of IFM Therapeutics LLC...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...and VP of business development, licensing and strategy at Novartis AG (NYSE:NVS; SIX:NOVN). Immunotherapy company IFM Therapeutics LLC...
...VP of U.S. exploratory development and strategic planning; he has written several books since then. BioCentury Staff IFM Therapeutics LLC Cambrex...
BioCentury | Dec 11, 2019
Finance

Omega seeking broad swath of deal types for $438M sixth fund

...about half a dozen investments, he said. In addition to Nuvation, they include asset-focused company IFM Therapeutics LLC...
BioCentury | Dec 2, 2019
Financial News

IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries

...the financing, joined by existing investors Atlas Venture and Abingworth. The new funds will enable IFM Therapeutics LLC...
...NLR family pyrin domain containing 3; STING (TMEM173) - Transmembrane protein 173 Val Kennedy, Associate Editor IFM Therapeutics LLC Bristol-Myers...
BioCentury | Sep 5, 2019
Company News

In third pharma deal, IFM partners cGAS-STING unit with Novartis

...in upfront and milestone payments. Lina Gugucheva, VP of business development, operations & strategy at IFM Therapeutics LLC...
...IFM Due is developing antagonists of cGAS and STING for inflammatory, autoimmune and neuroinflammatory diseases. IFM Therapeutics LLC...
...acquisition for the biotech and its predecessor, IFM Therapeutics Inc., and the second with Novartis. IFM Therapeutics LLC...
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

...are beginning to eye the next crop of inflammasome targets. At least two companies -- IFM Therapeutics LLC...
...last two years. Most recently, in April, Novartis AG acquired the IFM Tre subsidiary of IFM Therapeutics LLC...
...antagonists: a gut-directed compound to treat IBD and a CNS-penetrant molecule to treat neurodegenerative diseases. IFM Therapeutics LLC...
BioCentury | Apr 12, 2019
Product Development

NLRP3 early and often

...acquired by Novartis AG, based on preclinical data. In the deal, announced April 1, the IFM Therapeutics LLC...
...unit acquired in November, giving the pharma access to a preclinical pipeline of NLRP3 inhibitors. IFM Therapeutics LLC...
...founding investor in IFM Therapeutics Inc. and IFM Tre. Gladstone is a board observer for IFM Therapeutics LLC...
Items per page:
1 - 10 of 28
BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...in IFM Therapeutics Inc., the post-acquisition spinout IFM Therapeutics LLC...
...for inflammation was spun out into the IFM Therapeutics LLC...
...TMEM173) - Transmembrane protein 173 Paul Bonanos IFM Therapeutics Inc. IFM Therapeutics LLC Scorpion...
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...subsequent products (see “BMS Expanding I-O Portfolio” ). After spinning out of IFM Therapeutics Inc., IFM Therapeutics LLC...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

...space has a history of attracting pharma BD. In addition to the Jecure acquisition, inflammasome-focused IFM Therapeutics LLC...
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...Ilaris canakinumab for various autoimmune and inflammatory indications. Last year, Novartis acquired two subsidiaries of IFM Therapeutics LLC...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...and VP of business development, licensing and strategy at Novartis AG (NYSE:NVS; SIX:NOVN). Immunotherapy company IFM Therapeutics LLC...
...VP of U.S. exploratory development and strategic planning; he has written several books since then. BioCentury Staff IFM Therapeutics LLC Cambrex...
BioCentury | Dec 11, 2019
Finance

Omega seeking broad swath of deal types for $438M sixth fund

...about half a dozen investments, he said. In addition to Nuvation, they include asset-focused company IFM Therapeutics LLC...
BioCentury | Dec 2, 2019
Financial News

IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries

...the financing, joined by existing investors Atlas Venture and Abingworth. The new funds will enable IFM Therapeutics LLC...
...NLR family pyrin domain containing 3; STING (TMEM173) - Transmembrane protein 173 Val Kennedy, Associate Editor IFM Therapeutics LLC Bristol-Myers...
BioCentury | Sep 5, 2019
Company News

In third pharma deal, IFM partners cGAS-STING unit with Novartis

...in upfront and milestone payments. Lina Gugucheva, VP of business development, operations & strategy at IFM Therapeutics LLC...
...IFM Due is developing antagonists of cGAS and STING for inflammatory, autoimmune and neuroinflammatory diseases. IFM Therapeutics LLC...
...acquisition for the biotech and its predecessor, IFM Therapeutics Inc., and the second with Novartis. IFM Therapeutics LLC...
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

...are beginning to eye the next crop of inflammasome targets. At least two companies -- IFM Therapeutics LLC...
...last two years. Most recently, in April, Novartis AG acquired the IFM Tre subsidiary of IFM Therapeutics LLC...
...antagonists: a gut-directed compound to treat IBD and a CNS-penetrant molecule to treat neurodegenerative diseases. IFM Therapeutics LLC...
BioCentury | Apr 12, 2019
Product Development

NLRP3 early and often

...acquired by Novartis AG, based on preclinical data. In the deal, announced April 1, the IFM Therapeutics LLC...
...unit acquired in November, giving the pharma access to a preclinical pipeline of NLRP3 inhibitors. IFM Therapeutics LLC...
...founding investor in IFM Therapeutics Inc. and IFM Tre. Gladstone is a board observer for IFM Therapeutics LLC...
Items per page:
1 - 10 of 28